TY - JOUR T1 - SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers JF - medRxiv DO - 10.1101/2021.06.29.21259500 SP - 2021.06.29.21259500 AU - Francesca Rovida AU - Irene Cassaniti AU - Stefania Paolucci AU - Elena Percivalle AU - Antonella Sarasini AU - Antonio Piralla AU - Federica Giardina AU - Jose Camilla Sammartino AU - Alessandro Ferrari AU - Federica Bergami AU - Alba Muzzi AU - Viola Novelli AU - Alessandro Meloni AU - Sara Cutti AU - Anna Maria Grugnetti AU - Giuseppina Grugnetti AU - Claudia Rona AU - Marinella Daglio AU - Carlo Marena AU - Antonio Triarico AU - Daniele Lilleri AU - Fausto Baldanti Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/22/2021.06.29.21259500.abstract N2 - Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58-93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p=0.001). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Fondazione Cariplo [grant CoVIM, no. 2020-1374] and Ministero della Salute, Ricerca Finalizzata [grants no. COVID-2020-12371760 and COVID-2020-12371817]. AP and FB have received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 101003650.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study procedures were approved by Fondazione IRCCS Policlinico San Matteo. Ethics approval was provided by "Comitato Etico Area Pavia" (Procedures no. 20200101361 and 2021000232).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. ER -